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ABSTRACT
Background: Lumbar spinal stenosis (LSS) is a growing health problem and a leading cause of disability and loss of
independence in older adults. It is usually caused by age-related degenerative narrowing of the spinal canals leading to
compression and ischemia of the spinal nerves and symptoms of neurogenic claudication. Limited walking ability is
the dominant functional impairment caused by LSS. Animal studies suggest increased blood flow to the spinal nerves
and spinal cord with superficial paraspinal electrical stimulation. The purpose of this study is to assess thea Institute of
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Methods/Design: We propose to conduct a 2-arm double-blinded (participant and assessor) randomized controlled
trial. We will recruit individuals who have limited walking ability due to degenerative LSS from hospital specialists,
community physicians, and chiropractors located in the city of Toronto, Canada. Eligible consenting participants will
be randomly assigned to either paraspinal TENS or placebo paraspinal TENS applied while walking. The primary
outcome will be walking distance measured during a single self-paced walking test. We will calculate the differences
in proportions among participants in both groups who achieve at least a 30% improvement in walking distance from
baseline using Pearson χ2 test with 95% confidence intervals.
Discussion: Effective nonoperative interventions for LSS are unknown. Interventions that can improve blood flow to
the spinal nerves while walking may increase walking ability in this population. Transcutaneous electrical nerve
stimulation is a low-cost intervention that may have the potential to achieve this objective. To our knowledge, this
study will be the first clinical trial to assess the effects of TENS on walking ability of patients with LSS.
Trial Registration: ClinicalTrials.gov ID: NCT02592642 (J Chiropr Med 2016;15:197-203)
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the dominant functional impairment due to LSS.3 Those
afflicted have greater walking limitations than individuals
with knee or hip osteoarthritis4 and greater functional
limitations than those with congestive heart failure, chronic
obstructive lung disease, or systemic lupus erythematosis.2
The clinical syndrome of LSS is known as neurogenic
claudication. It is characterized by bilateral or unilateral
buttock and lower extremity pain, heaviness, numbness,
tingling, or weakness precipitated by walking and standing
and relieved by sitting and bending forward.3,5 Claudica-
tion symptoms are believed to arise because of ischemia of
the spinal nerves secondary to venous congestion within the
spinal canals.6,7 This is plausible based on the rapid
symptom reduction with sitting and stooping forward.
Standing and walking postures increase both the lumbar
lordosis and axial load that leads to further narrowing of the
canals.8–10 A narrowed spinal canal impairs venous return
and leads to engorgement of the venous plexus.6 Engorge-
ment of the venous plexus blocks the flow of cerebral spinal
fluid within the epidural space, leading to further
congestion.6 Venous and cerebral spinal fluid congestion
increases with time standing or walking and eventually
compromises arterial perfusion and leads to hypoxia of the
spinal nerves and symptoms of claudication.6 Sitting and/or
stooping forward increases the canal size, relieves epidural
pressure, and restores blood flow to the spinal nerves.10
Nonoperative treatments aimed at a reduction of spinal
congestion and/or increase in blood flow to the spinal
nerves while walking may improve symptoms of neuro-
genic claudication. Recent evidence from animal models
suggests that transcutaneous electrical nerve stimulation
(TENS) to specific dermatomes results in a significant
increase in blood flow to somatotopically linked spinal cord
segments.11 Other animal models demonstrate an increase
in blood flow to the lumbar spinal cord and cauda equina
with electrical stimulation of the sciatic nerve.12
There are numerous human studies demonstrating
significant reduction in laboratory-induced ischemic pain
in the lower and upper extremities with the application of
superficial TENS vs a placebo TENS.13–17 A recent pilot
study of 12 patients with limited walking ability due to
neurogenic claudication and 13 age-matched controls
demonstrated that 5 minutes of superficial electrical
stimulation of the tibial nerve before a walk test significantly
improved walking distance.18 The authors speculated that
the nerve stimulation improves blood flow and oxygenation
to the spinal nerves of the cauda equina. At present, there are
no randomized controlled trials (RCTs) evaluating the
effectiveness of TENS applied while walking to patients
with neurogenic claudication due to LSS.
The purpose of this article is to describe a protocol for a
randomized controlled trial comparing the effectiveness of
TENS in improving walking capacity among individuals
with neurogenic claudication. Specifically, we propose tocompare the change in walking capacity from baseline
when using active superficial paraspinal TENS vs placebo
superficial paraspinal TENS applied while walking. We
hypothesize that paraspinal TENS used while walking will
be more effective in improving walking capacity than
placebo TENS.METHODS
Design
We will conduct a 2-arm double-blinded (participant and
assessor) single-session RCT (Fig 1). A single session
means that the intervention and the assessment of walking
ability will occur at the same time in a single session. This
will be a nested study within a larger RCT.19Study Setting and Source Population
Eligible participants are individuals who consult with
specialists (orthopedists, neurosurgeons, rheumatologists,
neurologists, or physiatrists), family physicians, or chiro-
practors for symptoms suggestive of neurogenic claudica-
tion at 1 of 7 hospitals and several community clinics in
Toronto, Canada, and the surrounding area.Recruitment
Participating physicians and chiropractors will identify
potential participants using an eligibility checklist (Fig 2).
Eligible potential participants will be given a pamphlet
outlining information concerning the study and providing
contact information for the trial coordinator. Interested and
potentially eligible participants will be asked to contact the
trial coordinator directly. Pamphlets will also be available in
patient waiting rooms of participating hospital clinics and
community clinics. Similar information will be advertised
in local newspapers to enhance recruitment. The trial
coordinator will provide details about the study and answer
questions by phone. The coordinator will confirm eligibility
including age, duration of symptoms, and self-reported
walking ability. Walking ability will be assessed by the
participants’ response to the question “Are you able to walk
continuously for 30 minutes without aids or without
stopping to rest or stooping forward to alleviate your
symptoms?” Self-reported walking ability has been shown
to be highly correlated (r = 0.80) to the Self-Paced Walk
Test (SPWT).20 Only interested participants who respond
“No” and meet the other inclusion/exclusion criteria will be
given an appointment for an intake assessment at the study
site (at Mount Sinai Hospital in Toronto, Canada).Eligibility Criteria
At the intake assessment, potential participants will be
assessed by a licensed practitioner. The assessment will
confirm eligibility (Fig 2) and will include a history,
Randomization
* SPWT = Self Paced Walking Test
Single SPWT with Device applied during the SPWT
a
Para-Spinal 
TENS (52)
Patients identified with neurogenic claudication due 
to lumbar spinal stenosis by participating specialist
Research Clinic: Assessment, check inclusion/exclusion 
criteria, informed consent, baseline assessment and
Self paced walking test (SPWT) 
b
Para-Spinal 
Placebo 
TENS (52)
Fig 1. Process of recruitment, randomization, and outcomes
assessment. TENS, transcutaneous electrical nerve stimulation.
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provided by the referring specialist. Following the assess-
ment, eligible and willing participants will be asked by the
research coordinator to provide informed written consent to
participate in the study. Consenting participants will be
asked to complete a baseline questionnaire and a short
physical performance battery21 and perform a 30-minute
SPWT20 (Fig 3).Allocation and Randomization to Treatment Groups
All participants will be randomly allocated to either
paraspinal TENS or paraspinal placebo TENS. The
randomization sequence will be prepared by the study
biostatistician ahead of recruitment using a computerized
random numbers table (NQuery Advisor 7.022). The
biostatistician will provide the trial coordinator with
sequentially numbered sealed opaque envelopes that will
contain treatment allocation. The study biostatistician will
not be involved in the selection, treatment, or follow-up of
participants.INTERVENTIONS AND CONTROLS
All participants will return within 1 week from the
baseline assessment for the intervention.
1. Paraspinal TENS: Participants randomized to this
subgroup will have disposable self-adhesive electrical
pads (Blue Sensor P, Ambu A/S, Denmark) applied over
the paraspinal musculature from L3 to S1 by a licensed
practitioner. The electrodes will be connected to a TENS
machine (NeuroTrac TENS from Verity Medical Ltd
[UK]) which will be worn by the subject concealedwithin a waist pouch. The TENS will be programmed for
a frequency of 65-100 Hz modulated over 3-second
intervals with a pulse width of 100-200 μsec, and turned
on 2 minutes before the start and during the SPWT.
Current intensity will be set to the level of comfort of the
patient, approximately 3 mA in pilot experiments, and
below the level causing muscle twitch.
2. Paraspinal transient placebo TENS: Participants random-
ized to this subgroup will have disposable self-adhesive
electrical pads (Blue Sensor P, Ambu A/S, Denmark)
applied over the paraspinal muscular from L3 to S1 by a
licensed practitioner. The electrodes will be connected to
a TENSmachine (NeuroTrac TENS fromVerityMedical
Ltd [UK]) which will be worn by the subject concealed
within a waist pouch. The TENS will be programmed
using a transient placebo frequency and intensity
according to the protocol of Rakel et al,23 that is, the
unit active for the first 30 seconds then ramping down to
zero stimulus over 15 seconds and worn from 2 minutes
before the start and during the SPWT.Blinding
Participants will perform a single SPWT while wearing
their assigned device. All SPWTs will be performed and
recorded by blinded assessors. Blinding will be achieved by
having participants wear hospital gowns and concealing
TENS units within zippered waist pouches. Participants
will be instructed not to communicate with the assessor
beyond answering questions that are part of the self-paced
walking test. The licensed practitioner will be nearby during
the assessment should the participant experience any
discomfort or difficulties related to the wearing the device.
Every effort will be made to ensure that the assessor does
not become unblinded during the assessment.OUTCOMES
Primary OutcomeObjective Walking Capacity. Walking capacity will be
assessed using the SPWT. The test requires subjects to walk
on a level surface without support at their own pace until
forced to stop due to symptoms of LSS or a time limit of 30
minutes.24Test termination will be defined as a complete
stop of 3 seconds. A blinded assessor will follow 1 m
behind the subject, without conversing, with a distance
instrument (Lufkin Pro-Series Model PSMW38) and
stopwatch. Distance walked and time to test termination
will be recorded. The SPWT is considered the criterion
standard with high validity for assessing walking capacity
in this population because it directly observes walking
ability under conditions representative of a real-world
setting.20,25 It has high test-retest reliability (intraclass
correlation coefficient = 0.98).24 The minimal clinically
Inclusion criteria
1. Age greater or equal to 50 years
2. Clinical symptoms of back and/or radiating lower limb or buttock 
pain; fatigue or loss of sensation in the lower limbs aggravated by 
walking and/or standing and relieved by sitting.
3. Intermittent or persistent pain without progressive neurological 
dysfunction
4. Duration of symptoms and signs for more than 3 months
5. Imaging confirmed spinal canal narrowing using MRI, CT scan, 
myelography or ultrasound
6. Clinical signs and symptoms corresponding to segmental level of  
narrowing identified by imaging
7. Patients with degenerative spondylolisthesis are included
8. Not considered to be a surgical candidate (in the next 12 months) 
or patient unwilling to have surgery
9. Able to perform mild-moderate exercise
10. Able to walk without assistive devices for at least 20 metres and 
less than 30 minutes continuously
11. Able to give written informed consent and complete interviews 
and questionnaires in English.
Exclusion criteria
1. Severe degenerative stenosis with intractable pain and progressive 
neurological dysfunction
2. Lumbar spinal stenosis not caused by degeneration
3. Lumbar herniated disc diagnosed during the last 12 months
4. Previous back surgery for lumbar spinal stenosis or instability
5. Underlying spinal disorder such as ankylosing spondylitis, 
neoplasm, infection or metabolic disease
6. Intermittent claudication due to vascular disease
7. Severe osteoarthrosis or arthritis of lower extremities causing 
limited walking ability
8. Neurologic disease causing impaired function of the lower limbs, 
including diabetes
9. Psychiatric disorders and /or cognitively impaired
Fig 2. Inclusion and exclusion criteria. CT, computed tomography; MRI, magnetic resonance imaging.
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population is unknown.STATISTICAL ISSUES
Sample Size
We have estimated the sample size for the primary
outcome of objective walking capacity based on an estimate
of the difference in the proportion of participants who
achieve an MCID in walking distance from baseline.
Because the MCID for the SPWT is unknown, we will
estimate it to be an improvement in walking distance from
baseline of 30% or more. We estimate that a total of 30% of
participants will achieve the estimated MCID in theparaspinal TENS placebo group and 60% in the paraspinal
TENS group. Based on an estimate of 30% difference in
proportions, a power of 0.8, an α of .05, and an estimated
dropout rate of 20%, a minimum of 52 participants per
group is estimated to be required to achieve significance
using a 2-tailed t test for 2 independent proportions.26Statistical Analysis
Baseline status of treatment groups will be compared
using 2-tailed independent-samples t tests, χ2 tests of
independence, and Mann-Whitney U tests as indicated.
Our analyses will be based on the “intention to treat”
principle.
Measures
Socio-demographic characteristics
Duration of symptoms (back or leg) 
Dominant pain (back or leg)
Co-Morbidity Disease Index 
Self-Paced Walking Test
Zurich Claudication Questionnaire (ZCQ) 
Symptom and Functional scales
Oswestry Disability index (ODI) and ODI walk
Numerical rating scale for back pain
Numerical rating scale for leg pain
36-item short-form health survey (V2)
Center for Epidemiological Studies-Depression Scale (CES-D
Short Physical Performance Battery (SPPB)
Falls Efficacy Scale (FES)
Fig 3. Measures collected at baseline.
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calculating the differences in proportions meeting the
MCID between the 2 groups using Pearson χ2 test with
95% confidence intervals (CIs). We will also calculate the
relative risk with 95% CIs among participants in both
groups who achieve the MCID. To control for potential
confounding (sex, education, perceived health status,
dominant leg or back pain, and hospital), logistic regression
models and generalized estimation equation methods will
be used.27 These models will control for baseline
differences not balanced by randomization.PROTECTION OF HUMAN SUBJECTS AND ASSESSMENT OF
SAFETY
Protection of Human Subjects
The study protocol has been approved by the Mount
Sinai Hospital (Toronto, Canada) Research Ethics Board
(certificate number 14-0020). This proposed trial has been
registered with ClinicalTrials.gov ID: NCT02592642.Adverse Events
We will measure the presence of adverse events that
may be associated with each intervention during the
SPWT. We will define adverse event as an unintended
sign or symptom of the intervention. These include
significant increase in back and/or lower extremity pain,
numbness, tingling, tiredness, or claudication symptoms
beyond those normally experienced when walking. We
will compute the incidence (95% CI) of each adverse
event listed above. The total number of participants will
be used as the denominator. Any adverse event that is
life threatening or associated with significant disability
will be reported to the Mount Sinai Hospital Ethics
Review Board.Data Management
Data will be entered electronically using a pretested
tablet. Deidentified data will be stored electronically using a
secure data warehouse. A random set of 20% of the data
will be evaluated for accuracy. No data monitoring
committee will be necessary because of the low risk of
harm and because the intervention and assessment will be
performed once at the same time with no other follow-up
assessments.
Dissemination Policy. We plan to publish the results in an
open access document in a scientific journal and commu-
nicate findings to participants via an e-mail newsletter.
Public dissemination will also take place through
sponsor-initiated publications and multimedia platforms
(The Arthritis Society).DISCUSSION
We propose a protocol for an RCT to assess whether
the application of TENS while walking can improve
walking ability in patients with LSS. There are no
published RCTs assessing TENS while walking for LSS.
The rationale for this study is based on the proposed
pathophysiology of LSS that symptoms of claudication
are due to compromised blood flow to the spinal nerves
when walking.6 Animal studies suggest that improved
blood flow to the spinal cord and cauda equina can be
achieved with superficial electrical stimulation either at
the paraspinal level or to peripheral nerves of the lower
limb.12,11 A recent small case-controlled human study
showed improved walking ability with stimulation of the
tibial nerve before walking.18 Because neuroischemia
occurs at the spinal level during walking to give rise to
claudication, interventions that can improve blood flow
to the cauda equina during walking may reduce
symptoms and improve walking ability. TENS applied
at the paraspinal level while walking may potentially
achieve this. If shown to be beneficial, TENS can be a
low-cost treatment for some individuals with LSS.
We selected an RCT design because it is the study
design of choice when comparing the effectiveness of
interventions. This study will be nested within a larger
RCT, which is feasible because the TENS interventions to
be tested can be performed independently before the start
of the larger study without impacting the outcome (walking
capacity) of the TENS interventions or the outcomes of the
larger study. Walking capacity while using the TENS
interventions will be measured in a single session using the
SPWT with no other follow-up assessments. Walking
capacity will be compared with a baseline SPWT. The
SPWT is the current criterion standard for measuring
objective walking capacity in LSS because it assesses
walking ability in a real-life setting.24
Practical Applications
• Effective nonoperative treatments for LSS are
unknown.
• At this time, there are no human randomized
clinical trials evaluating TENS applied while
walking in spinal stenosis.
• Transcutaneous electrical nerve stimulation is a
practical low-cost self-management intervention
that may improve blood flow to the spinal nerves
and reduce symptoms and functional limitations
of neurogenic claudication.
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connected by 2 shorter hallways forming a large rectangular
area (140 m long) where participants easily can perform the
SPWT.
However, the SPWT has a ceiling effect in that the
test measures distance traveled for a maximum of a
30-minute period. For this reason, we will only include
participants who are more severely impaired and cannot
complete the SPWT during the baseline assessment.
We will implement strict rules preventing the com-
munication regarding participant allocation among par-
ticipants, research coordinator, and blinded assessors. We
will also test whether the blinding of the interventions
(active or placebo) was successful by asking participants
which intervention (the TENS or the placebo TENS) they
believe they received following the completion of
the SPWT.
Lumbar spinal stenosis causing neurogenic claudication
is a growing problem due to the aging population. In
Japan where 25% of the population is older than 65 years,
about 12 million people have LSS.28 In the United States,
in the year 2030, it is estimated that 73 million people will
be older than 65 years29 and about 30% will have
symptoms of LSS.30 There is no cure for LSS, and
although LSS is the most common reason for surgery in
older adults,31 the vast majority of people with LSS do
not have surgery but receive nonsurgical care.31 However,
what constitutes effective nonsurgical treatment is
unknown.32–35 High-quality RCTs are needed to assess
nonoperative treatment options both new and existing.CONCLUSION
Effective nonoperative interventions for LSS are
unknown. Interventions that can improve blood flow to
the spinal nerves while walking may increase walking
ability in this population. Transcutaneous electrical nerve
stimulation is a low-cost intervention that may have the
potential to achieve this objective. To our knowledge, this
study will be the first clinical trial to assess the effects of
TENS on walking ability of patients with LSS.FUNDING SOURCES AND CONFLICTS OF INTEREST
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